{"prompt": "['FLUAD vs Fluzone-HD', 'Version 5.0', 'September 25, 2018', '4.4 Reasons for and Handling of Withdrawals', 'The following may be reason for study withdrawal:', 'As deemed necessary by the principal investigator (PI).', 'Subject withdrawal of consent.', 'Loss to follow-up.', 'Subject unable to return for study appointments', 'Termination of the study by the sponsor.', 'Subjects not meeting eligibility criteria in the repeat vaccination study will be withdrawn', 'at the time this is determined', 'Subjects may withdraw their consent for study participation at any time and for any reason,', 'without penalty. Subjects who withdraw from the study prior to randomization will be replaced.', 'Subjects who withdraw from the study after randomization will not be replaced. Data collected', 'before withdrawal will still be used for analysis.', '4.5 Termination of Study', 'This study may be terminated for safety concerns of the principal investigators from the Lead or', 'Contributing sites, CDC, or participating Institutional Review Boards (IRBs).', '5 STUDY SCHEDULE, PROCEDURES, & EVLAUTIONS', '5.1 Schedule of events and data collection', 'Persons meeting the proposed eligibility criteria (Section 4) will be recruited. Written informed', 'consent (Appendix A) will be obtained from study participants prior to conducting any study', 'procedures. Prescreening may take place over the phone prior to Visit 1. Table 1 describes the', 'schedule of study visits with further details below.', 'Table 1. Visit Schedule', 'Visit 4', 'Visit 6', 'Visit 1', 'Visit 2', 'Unscheduled', 'Visit 3', 'Visit 5', 'Procedure', 'Day 1', 'Day 3 + 2', 'Visit', 'Day 9 + 3', 'Day 29 + 7', 'Day 43 + 7', 'Day 181 +', '14', 'Type of contact', 'Phone or', 'Phone or', 'Phone or', 'Clinic', 'Clinic', 'Clinic', 'Clinic', 'Clinic', 'Clinic', 'Clinic', 'Informed consent &', 'Medical Release of', 'X', 'Information', 'Review Eligibility', 'Criteria', 'Cognitive', 'X', 'Assessment', 'Sociodemographics', 'Medical history', 'X', 'X', 'X', 'X', 'X', 'X', 'Medications,', 'X', 'X', 'X', 'X', 'X', 'X', 'including statins', 'Influenza Vaccination', 'History', 'Vital', 'X', 'X', 'X', 'X', 'signs/temperature', 'Body mass index', 'X', 'X', 'Obtain health-related', 'quality of life', 'X', 'Xe', 'assessment', '18']['FLUAD vs Fluzone-HD', 'Version 5.0', 'September 25, 2018', 'Visit 4', 'Visit 6', 'Visit 1', 'Visit 2', 'Unscheduled', 'Visit 3', 'Visit 5', 'Procedure', 'Day 1', 'Day 3 + 2', 'Visit', 'Day 9 + 3', 'Day 29 + 7', 'Day 43 + 7', 'Day 181 +', '14', 'Participant', 'perception of', 'Xd', 'Xd', 'Xd', 'vaccination', 'Baseline', 'X\u00b0', 'reactogenicity', 'Venipuncture', 'X', 'X', 'X', 'Randomization', 'Xd', 'Vaccination', 'X', 'Diary & supplies', 'Assess for injection', 'site pain at least 15', 'min. after', 'immunization', 'At> 15 min. assess', 'for any immediate', 'reactogenicity', 'symptoms', 'Obtain solicited', 'X', 'Xb', 'X', 'adverse events', 'Obtain unsolicited', 'X', 'X', 'X', 'X', 'X', 'adverse events', 'Obtain SAE', 'information, AEs of', 'clinical interest, and', 'X', 'X', 'X', 'X', 'X', 'new onset medical', 'conditions', 'Obtain health care', 'X', 'X', 'utilization data', 'aFor subset of approximately 100 subjects receiving third blood draw 6 months post-vaccination in 2017-18', 'bor unscheduled visits, solicited AEs will be collected only for days 9', 'Baseline reactogenicity will be performed before venipuncture and vaccination', 'does not apply to subjects participating in the Year 2 repeat vaccination during study Year 2', 'Will collect Day 3 and Day 9 health related quality of life instruments (EQ-5D-5L and Vaccine Reaction', 'Questionnaire) on V3 phone call', 'Visit 1, Study Day 1 - Screening, Enrollment, and Vaccination (Clinic Visit)', 'Obtain written informed consent and release of medical record information', 'Note: In Year 2, subjects participating in the sub-study on repeat vaccination will', 'sign a new consent form', 'Determine if subject will participate in long term immunogenicity sub-study or repeat', 'vaccination sub-study (Year 1 only)', 'Review and confirm study eligibility', 'Perform cognitive assessment with the Mini-Cog tool22 (and RUDAS if needed)(Appendix', 'B,C)', 'Scores 3-5 on MiniCog will be eligible', 'Scores 0-1 on MiniCog will be ineligible', 'Scores of 2 on MiniCog: person will undergo further screening with RUDAS. If', 'person scores 23 or higher (range = 0-30), they will be eligible.', 'Potential participants may have low scores on the cognitive screening tests and be', 'ineligible for the study. In this case, the study doctor or designee will review the', \"results with the individual and recommend follow-up with the individual's health care\", 'provider.', '19']\n\n###\n\n", "completion": "END"}